| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $58,475,639 | 68 | 100 |
| Quart Barry D | director | 0 | $0 | 8 | $2.51M | $-2.51M |
| Moat Ross | CHIEF COMMERCIAL OFFICER | 0 | $0 | 6 | $3.74M | $-3.74M |
| Megna Michael R | CHIEF ACCOUNTING OFFICER | 0 | $0 | 6 | $4.01M | $-4.01M |
| Paolini John F. | CHIEF MEDICAL OFFICER | 0 | $0 | 3 | $4.03M | $-4.03M |
| Malley Thomas | director | 0 | $0 | 3 | $5.86M | $-5.86M |
| Ragosa Mark | CHIEF FINANCIAL OFFICER | 0 | $0 | 13 | $8.75M | $-8.75M |
| Patel Sanj K | CHAIRMAN & CEO | 0 | $0 | 10 | $12.68M | $-12.68M |
| Tessari Eben | CHIEF OPERATING OFFICER | 0 | $0 | 19 | $16.9M | $-16.9M |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Over the last 12 months, insiders at Kiniksa Pharmaceuticals, Ltd. have bought $0 and sold $58.48M worth of Kiniksa Pharmaceuticals, Ltd. stock.
On average, over the past 5 years, insiders at Kiniksa Pharmaceuticals, Ltd. have bought $0 and sold $19.47M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,686,704 shares for transaction amount of $31.99M was made by Flynn James E (10 percent owner) on 2018‑05‑29.
| 2026-02-12 | Sale | Quart Barry D | director | 2,690 0.0037% | $45.00 | $121,050 | +0.85% | |
| 2026-02-09 | Sale | Ragosa Mark | CHIEF FINANCIAL OFFICER | 17,845 0.0238% | $43.28 | $772,254 | +0.42% | |
| 2026-02-04 | Sale | Quart Barry D | director | 2,602 0.0037% | $45.02 | $117,142 | +0.14% | |
| 2026-02-03 | Sale | Quart Barry D | director | 12,528 0.0172% | $45.27 | $567,143 | -1.46% | |
| 2026-02-02 | Sale | Quart Barry D | director | 830 0.0011% | $45.00 | $37,350 | -1.09% | |
| 2026-01-08 | Sale | Ragosa Mark | CHIEF FINANCIAL OFFICER | 12,000 0.0164% | $41.89 | $502,680 | +3.86% | |
| 2025-12-15 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 12,048 0.0164% | $41.56 | $500,715 | +2.45% | |
| 2025-12-15 | Sale | Quart Barry D | director | 20,129 0.0274% | $41.51 | $835,555 | +2.45% | |
| 2025-12-08 | Sale | Ragosa Mark | CHIEF FINANCIAL OFFICER | 42,841 0.0584% | $41.49 | $1.78M | +2.09% | |
| 2025-11-26 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 200 0.0003% | $42.89 | $8,578 | -1.26% | |
| 2025-11-17 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 12,470 0.0169% | $41.24 | $514,224 | +1.45% | |
| 2025-11-12 | Sale | Ragosa Mark | CHIEF FINANCIAL OFFICER | 19,900 0.029% | $40.94 | $814,706 | +3.46% | |
| 2025-10-31 | Sale | Paolini John F. | CHIEF MEDICAL OFFICER | 82,542 0.1134% | $37.14 | $3.07M | +12.48% | |
| 2025-10-28 | Sale | Ragosa Mark | CHIEF FINANCIAL OFFICER | 100 0.0001% | $41.00 | $4,100 | +5.45% | |
| 2025-10-22 | Sale | Patel Sanj K | CHAIRMAN & CEO | 97,390 0.1312% | $38.83 | $3.78M | +6.81% | |
| 2025-10-21 | Sale | Patel Sanj K | CHAIRMAN & CEO | 39,331 0.053% | $38.77 | $1.52M | +6.87% | |
| 2025-10-20 | Sale | Patel Sanj K | CHAIRMAN & CEO | 121,248 0.1632% | $38.90 | $4.72M | +6.41% | |
| 2025-10-20 | Sale | Megna Michael R | CHIEF ACCOUNTING OFFICER | 50,490 0.0679% | $38.87 | $1.96M | +6.41% | |
| 2025-10-14 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 12,368 0.0166% | $37.67 | $465,843 | +9.26% | |
| 2025-09-29 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 42,000 0.056% | $38.33 | $1.61M | +5.98% |
| Patel Sanj K | CHAIRMAN & CEO | 111794 0.1525% | $5.07M | 1 | 21 | |
| Paolini John F. | CHIEF MEDICAL OFFICER | 61324 0.0837% | $2.78M | 0 | 15 | |
| Megna Michael R | CHIEF ACCOUNTING OFFICER | 27046 0.0369% | $1.23M | 0 | 11 | |
| Tessari Eben | CHIEF OPERATING OFFICER | 16666 0.0227% | $756,303.08 | 0 | 27 | |
| Quart Barry D | director | 12546 0.0171% | $569,337.48 | 0 | 9 | |
| Malley Thomas | director | 12546 0.0171% | $569,337.48 | 0 | 3 | |
| Ragosa Mark | CHIEF FINANCIAL OFFICER | 12086 0.0165% | $548,462.68 | 0 | 19 | |
| Moat Ross | CHIEF CORP. & COMM. OFFICER | 9415 0.0128% | $427,252.70 | 0 | 7 | |
| BAKER BROS. ADVISORS LP | 2700597 3.6848% | $122.55M | 2 | 0 | +4.3% | |
| Cormorant Asset Management, LP | director | 900443 1.2286% | $40.86M | 1 | 0 | +4.3% |
| Flynn James E | 10 percent owner | 843352 1.1507% | $38.27M | 1 | 0 | +4.3% |
| Beetham Thomas W. | EVP & Chief Legal Officer | 297523 0.406% | $13.5M | 1 | 6 | |
| BOESS CARSTEN | 10 percent owner | 6392 0.0087% | $290,068.96 | 1 | 0 | |
| Heberlig Chris | Exec VP & CFO | 6392 0.0087% | $290,068.96 | 1 | 0 | |
| Mahoney Stephen F. | President & COO | 6392 0.0087% | $290,068.96 | 1 | 0 |
$66,736,176 | 136 | 27.54% | $3.69B | |
$52,263,649 | 70 | 1.18% | $3.8B | |
$11,588,217 | 69 | 42.07% | $3.03B | |
$104,428,685 | 44 | 22.55% | $2.94B | |
$148,770,544 | 34 | 80.63% | $3B | |
$1,275,975,557 | 32 | 19.44% | $3.88B | |
$61,717,660 | 28 | 36.84% | $3.57B | |
$5,066,938 | 27 | 26.38% | $3.22B | |
$150,253,463 | 26 | -52.83% | $3.35B | |
$27,105,902 | 21 | -16.06% | $3.85B | |
$137,061,250 | 16 | 23.01% | $3.26B | |
$174,105,409 | 15 | 10.88% | $2.73B | |
$92,580,864 | 14 | -1.28% | $3.18B | |
$1,248,715 | 10 | 5.66% | $2.85B | |
$1,711,150 | 9 | 31.59% | $3.52B | |
$461,215 | 5 | 10.35% | $4B | |
Kiniksa Pharmaceuticals, Ltd. (KNSA) | $142,493,653 | 3 | 4.30% | $3.33B |
$50,990,767 | 2 | 19.79% | $3.82B | |
$9,900,000 | 1 | -7.19% | $3.01B |
| Increased Positions | 105 | +44.12% | 6M | +14.33% |
| Decreased Positions | 101 | -42.44% | 5M | -11.89% |
| New Positions | 40 | New | 2M | New |
| Sold Out Positions | 22 | Sold Out | 576,079 | Sold Out |
| Total Postitions | 242 | +1.68% | 42M | +2.44% |
| Rubric Capital Management Lp | $168,020.00 | 8.89% | 4M | +90,194 | +2.31% | 2025-09-30 |
| Vanguard Group Inc | $128,667.00 | 6.81% | 3.06M | -68,467 | -2.19% | 2025-09-30 |
| Baker Bros. Advisors Lp | $118,650.00 | 6.28% | 2.82M | 0 | 0% | 2025-09-30 |
| Tang Capital Management Llc | $97,813.00 | 5.18% | 2.33M | 0 | 0% | 2025-09-30 |
| Fairmount Funds Management Llc | $74,468.00 | 3.94% | 1.77M | 0 | 0% | 2025-09-30 |
| Acadian Asset Management Llc | $67,986.00 | 3.6% | 1.62M | +350,532 | +27.64% | 2025-09-30 |
| Morgan Stanley | $57,250.00 | 3.03% | 1.36M | +296,644 | +27.82% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $47,641.00 | 2.52% | 1.13M | +342,881 | +43.33% | 2025-09-30 |
| Arrowstreet Capital, Limited Partnership | $44,872.00 | 2.37% | 1.07M | +332,846 | +45.26% | 2025-09-30 |
| Millennium Management Llc | $42,598.00 | 2.25% | 1.01M | -5,843 | -0.57% | 2025-09-30 |